The number of initial public offerings (IPOs) in 2016 grew by five last week, with a food distribution company leading the way with an offering that raised more than $1 billion. Two scheduled IPOs did not make it out the door and are currently listed as day-to-day for the coming week.
U.S. Foods Holding Corp. (NYSE: USFD) raised $1.02 billion at an IPO price of $23 per share. The stock added 9% to close the week. Reata Therapeutics Inc. (NASDAQ: RETA) raised $61 million by adding shares and cutting its IPO price to $11, well below the expected range of $14 to $16. Shares closed the week up 30% after a first day pop of $19.
Cotiviti Holdings Inc. (NYSE: COTV) raised $238 million but finished the week down 6% from the IPO price. GMS Inc. (NYSE: GMS) raised $147 million and finished the week up 7%, while Midland States Bancorp Inc. (NASDAQ: MSBI) raised $80 million and closed the week up 2%.
Through the week ending May 27, IPO ETF manager Renaissance Capital reported that 31 IPOs have priced in the United States so far this year, down about 55% from a year ago. Total proceeds raised through last week equaled $5.4 billion, down about 57% compared with the same period in 2015. Of the 31 IPOs that have gone off this year, 17 have come from the health care sector. Last year’s IPO total came in at $30 billion on 170 offerings. Renaissance Capital does not include “best efforts” or blank-check companies in its totals.
[nativounit]
The first of the coming week’s two new IPOs is Nant Health, a health care IT company. The company plans to sell 6.5 million shares in an expected price range of $12.50 to $15.50 to raise $91 million at an implied market cap of $1.65 billion. Joint bookrunners for the offering are Jefferies and Cowen. Co-managers are First Analysis Securities, Canaccord Genuity and FBR Capital Markets. Shares are expected to price Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol NH.
Sensus Healthcare is a medical device maker specializing in treating non-melanoma skin cancers and other skin conditions with superficial radiation therapy. The company plans to offer 1.8 million units at an IPO price $6.25 to raise $11 million at an implied market cap of $77.8 million. Each unit consists of one share of common stock and a three-year warrant to purchase another share of common stock at an initial exercise price of $7.80. Joint bookrunners for the IPO are Northland Securities and Neidiger, Tucker, Bruner. Shares are scheduled to price Thursday and begin trading Friday on the Nasdaq under the ticker symbol SRTSU.
The first of two companies listed as day-to-day this week is Cancer Prevention Pharmaceuticals, a clinical-stage biopharmaceutical company developing and commercializing therapeutic agents to treat and prevent certain pre-cancerous conditions, orphan diseases and gastrointestinal conditions. The company downsized it offering from 1.9 million shares to 1.3 million in an expected price range of $12 to $14 to raise $16.3 million at an implied market cap of $87.9 million. Sole bookrunner for the offering is Aegis Capital. Shares are expected to trade on the New York Stock Exchange under the ticker symbol CPP.
Clearside Biomedical, which is also listed as day to day, is a late-stage biopharmaceutical company developing drug therapies to treat blinding diseases. The company plans to offer 4 million shares in an IPO range of $14 to $16 to raise $60 million at an implied market cap of $244 million. Joint bookrunners for the offering are Cowen and Stifel. Co-managers are Needham and Wedbush PacGrow. Shares are expected to trade on the Nasdaq under the ticker symbol CLSD.
[wallst_email_signup]
Top Gaining Stocks
Top Losing Stocks